Tell us about your product or service.
Curewize Health Ltd. commercializes cutting-edge technologies for the advancement of personalized treatment of cancers common to children, adolescents and young adults. Our lead product is ProALL a prognostic and monitoring laboratory test for acute lymphoblastic leukemia. ProALL has the potential to change a complicated and lengthy treatment decision process to a simple and short process.
What inspired you to launch your business?
First and foremost, I want to do something good for the world. I’ve been in the personalized medicine field for 14 years, first as a PhD Student, then as a Senior Clinical Research Associate and finally as a Director of Clinical Development. After learning the business, which I love, I thought it would be great to start a new biotech company. I decided to focus on cancers common to young people after realizing that there is a lack of attention in this area, even though the return of investment can be very good both financially and in number of lives saved.
What problem does your business or organization solve?
The pediatric oncologist faces the dilemma of treating young acute lymphoblastic leukemia patients with therapies that can cause life-long medical conditions. Therefore, the oncologists treats the young patient with either standard or intense therapy, usually according to the patients response to their first round of treatment. With ProALL there is no need to wait and see the patient’s treatment response. The physician can receive ProALL results within 3 days of diagnosis, so the patient can be treated correctly from the start. We also have findings indicating that ProALL may be used to help monitor the patient’s ongoing treatment.
What has been your biggest challenge and how are you working to overcome it?
Before ProALL can be translated to clinical practice, we need to perform additional clinical studies and receive regulatory approval. The prototype is complete with good proof, so it will take around a year to receive regulatory approval. Afterwards, we will need to continue with studies to receive widespread approval from medical professionals, around 1-2 years. Our challenge is to find funding for this pre-commercialization stage. We are speaking to investors and applying for grants. We are also contemplating Crowd Funding, but for this we need a large social network.
Give us one word that people might use to describe you.
How has Project Eve helped you and/or your business?
Project Eve is helping by spreading the word on Curewize. We hope this will enlarge our Twitter following and introduce Curewize to funding sources. I still need to decide whether to go ahead with Crowd Funding. Post me your thoughts on Twitter. Thank you Project Eve!!!
Give us an insider tip that relates to your industry.
In many meetings that I attend I hear people say that they got into the biotech/biomed business, because they want to help other people.
Company: Curewize Health Ltd.
Follow my organization on social media here:
Project Eve is compiling the largest archive of female founders’ startup stories in the world to motivate women to think beyond traditional boundaries, support one another, embrace change and view challenges as opportunities. Please share your Startup Story today. All published content will be syndicated to over 300,000 friends, fans and followers. Project Eve welcomes submissions of original or republished content, stories. For more information, please refer to our Content Submissions Guidelines.